<DOC>
	<DOCNO>NCT01905228</DOCNO>
	<brief_summary>The primary objective study determine maximally tolerate dose recommend Phase 2 dose CBL0137 administer intravenously ( IV ) patient metastatic unresectable advanced solid malignancy .</brief_summary>
	<brief_title>A Phase 1 Trial CBL0137 Patients With Metastatic Unresectable Advanced Solid Neoplasm</brief_title>
	<detailed_description>Patients must document recurrent refractory solid tumor ; patient enrol dose-expansion part trial must least one lesion may qualify target lesion base RECIST 1.1 criterion . Following provision sign informed consent , patient screen entry study . Screening number assign site . Patients meet entry criterion screen data enter database .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients must histological cytological evidence solid neoplasm Patients enrol expansion cohort must least one measureable lesion define RECIST 1.1 criterion Patients must : metastatic unresectable advanced solid tumor recur progress follow standard therapy longer candidate standard therapy tumor standard therapy Patients must ambulatory ECOG Performance Score 0 1 ; Patients legal representative must able provide write informed consent ; Patients must adequate bone marrow reserve evidence : White Blood Cell Count ( WBC ) &gt; 3,000/µL Absolute Neutrophil Count ( ANC ) &gt; 1,500/µL Platelet count ( PLT ) &gt; 75,000/µL Hemoglobin ( HGB ) &gt; 8.0 gm/dL ( patient may transfuse achieve HGB level ) ; Patients must adequate hepatic function evidence : Serum AST/ALT &lt; 3X upper limit normal ( ULN ) reference lab ( &lt; 5X ULN patient know hepatic metastasis ) Serum bilirubin &lt; 1.5 x ULN reference lab ; Patients active infection fever &gt; 38.50 C within 3 day first schedule day dose ; Patients primary CNS tumor symptomatic CNS metastases undergone surgery and/or radiotherapy and/or neurologically stable ; Patients know hypersensitivity component CBL0137 ; Patients receive concurrent investigational therapy ; patient recently receive investigational therapy , 5 halflives must elapse last dose investigational drug first dose CBL0137 . If halflive unknown , 4 week must elapse last dose investigational drug first dose CBL0137 ( investigational therapy define treatment currently regulatory authority approve indication United States ) ; Males mean QTcF value &gt; 450 msec female QTcF value &gt; 470 msec follow 3 ECGs conduct 5 minute apart ; patient know congenital prolonged QT syndrome ; patient medication know cause prolong QT interval ECG ; Please speak PI complete Inclusion/Exclusion listing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic Advance Solid Neoplasms</keyword>
	<keyword>Unresectable Advance Solid Neoplasms</keyword>
</DOC>